{"DataElement":{"publicId":"3420754","version":"1","preferredName":"Patient Burkitt Lymphoma Classification Eligibility Determination Burkitt Lymphoma Risk Category","preferredDefinition":"For determining a Burkitt Lymphoma patient's classification._Allows for the categorization of a patient's Burkitt Lymphoma, as either high or low risk.","longName":"3420753v1.0:3420748v1.0","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"3420753","version":"1","preferredName":"Patient Burkitt Lymphoma Classification Eligibility Determination","preferredDefinition":"For determining a Burkitt Lymphoma patient's classification.","longName":"2183985v1.0:3420751v1.0","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2404694","version":"1","preferredName":"Patient","preferredDefinition":"Individuals participating in the health care system for the purpose of receiving therapeutic, diagnostic, or preventive procedures.","longName":"C0030705","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Patient","conceptCode":"C0030705","definition":"Individuals participating in the health care system for the purpose of receiving therapeutic, diagnostic, or preventive procedures.","evsSource":"UMLS_CUI","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0094ACAF-11CF-1BCA-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-09-12","modifiedBy":"ONEDATA","dateModified":"2005-09-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3420751","version":"1","preferredName":"Burkitt Lymphoma Classification Eligibility Determination","preferredDefinition":"A highly aggressive lymphoma composed of monomorphic medium-sized B-cells with basophilic cytoplasm and numerous mitotic figures.  It is often associated with the presence of Epstein-Barr virus (EBV) and is commonly seen in AIDS patients.  Three morphologic variants are recognized: classical Burkitt's lymphoma, Burkitt's lymphoma with plasmacytoid differentiation, and atypical Burkitt's/Burkitt's-like lymphoma.  All cases express the MYC translocation [t(8;14)]. (WHO, 2001):A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.:Criteria to determine eligibility of patients for medical care programs and services.","longName":"C2912:C25161:C25171","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Burkitt Lymphoma","conceptCode":"C2912","definition":"A highly aggressive lymphoma composed of monomorphic medium-sized B-cells with basophilic cytoplasm and numerous mitotic figures.  It is often associated with the presence of Epstein-Barr virus (EBV) and is commonly seen in AIDS patients.  Three morphologic variants are recognized: classical Burkitt lymphoma, Burkitt lymphoma with plasmacytoid differentiation, and atypical Burkitt/Burkitt-like lymphoma.  All cases express the MYC translocation [t(8;14)]. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Classification","conceptCode":"C25161","definition":"A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Eligibility Determination","conceptCode":"C25171","definition":"The act of determining if a subject is suitable for enrollment in a study according specific protocol criteria and procedures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BBF00FBB-9699-62A0-E040-BB89AD437544","latestVersionIndicator":"Yes","beginDate":"2012-03-23","endDate":null,"createdBy":"STAUFFEM","dateCreated":"2012-03-23","modifiedBy":"ONEDATA","dateModified":"2012-03-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BBF00FBB-96AA-62A0-E040-BB89AD437544","latestVersionIndicator":"Yes","beginDate":"2012-03-23","endDate":null,"createdBy":"STAUFFEM","dateCreated":"2012-03-23","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3420748","version":"1","preferredName":"Burkitt Lymphoma Risk Category","preferredDefinition":"Allows for the categorization of a patient's Burkitt Lymphoma, as either high or low risk.","longName":"3420748v1.0","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"High Risk (HR)","valueDescription":"High Risk (HR)","ValueMeaning":{"publicId":"3420749","version":"1","preferredName":"High Risk (HR)","longName":"3420749","preferredDefinition":"Patient meets all of the following criteria: All patients not considered low risk (LR) and all patients with c-MYC positive DLBCL or c-MYC positive PL","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BBF00FBB-964F-62A0-E040-BB89AD437544","latestVersionIndicator":"Yes","beginDate":"2012-03-23","endDate":null,"createdBy":"STAUFFEM","dateCreated":"2012-03-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BBF00FBB-9668-62A0-E040-BB89AD437544","beginDate":"2012-03-23","endDate":null,"createdBy":"STAUFFEM","dateCreated":"2012-03-23","modifiedBy":"ONEDATA","dateModified":"2012-03-23","deletedIndicator":"No"},{"value":"Low Risk (LR)","valueDescription":"Low Risk (LR)","ValueMeaning":{"publicId":"3420750","version":"1","preferredName":"Low Risk (LR)","longName":"3420750","preferredDefinition":"Patient meets all of the following criteria: Normal LDH, ECOG PS 0-1 or Karnofsky 100%-70%, Ann Arbor stage I-II, No tumor mass >= 7 cm","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BBF00FBB-9672-62A0-E040-BB89AD437544","latestVersionIndicator":"Yes","beginDate":"2012-03-23","endDate":null,"createdBy":"STAUFFEM","dateCreated":"2012-03-23","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BBF00FBB-968B-62A0-E040-BB89AD437544","beginDate":"2012-03-23","endDate":null,"createdBy":"STAUFFEM","dateCreated":"2012-03-23","modifiedBy":"ONEDATA","dateModified":"2012-03-23","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3420747","version":"1","preferredName":"Burkitt Lymphoma Risk Category","preferredDefinition":"A highly aggressive lymphoma composed of monomorphic medium-sized B-cells with basophilic cytoplasm and numerous mitotic figures.  It is often associated with the presence of Epstein-Barr virus (EBV) and is commonly seen in AIDS patients.  Three morphologic variants are recognized: classical Burkitt's lymphoma, Burkitt's lymphoma with plasmacytoid differentiation, and atypical Burkitt's/Burkitt's-like lymphoma.  All cases express the MYC translocation [t(8;14)]. (WHO, 2001):Risk is the potential future harm that may arise from some present action. It is often combined or confused with the probability of an event which is seen as undesirable. (from WIkipedia):Category; used informally to mean a class of things.","longName":"C2912:C17102:C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Burkitt Lymphoma","conceptCode":"C2912","definition":"A highly aggressive lymphoma composed of monomorphic medium-sized B-cells with basophilic cytoplasm and numerous mitotic figures.  It is often associated with the presence of Epstein-Barr virus (EBV) and is commonly seen in AIDS patients.  Three morphologic variants are recognized: classical Burkitt lymphoma, Burkitt lymphoma with plasmacytoid differentiation, and atypical Burkitt/Burkitt-like lymphoma.  All cases express the MYC translocation [t(8;14)]. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Risk","conceptCode":"C17102","definition":"The potential future harm that may arise from some present action. It is often combined or confused with the probability of an event which is seen as undesirable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BBF00FBB-962A-62A0-E040-BB89AD437544","latestVersionIndicator":"Yes","beginDate":"2012-03-23","endDate":null,"createdBy":"STAUFFEM","dateCreated":"2012-03-23","modifiedBy":"ONEDATA","dateModified":"2012-03-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BBF00FBB-963B-62A0-E040-BB89AD437544","latestVersionIndicator":"Yes","beginDate":"2012-03-23","endDate":null,"createdBy":"STAUFFEM","dateCreated":"2012-03-23","modifiedBy":"SBREXT","dateModified":"2016-09-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"In the opinion of the investi","type":"Preferred Question Text","description":"In the opinion of the investigator, the patient meets the criteria for the following risk level","url":null,"context":"CTEP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BBF00FBB-96BB-62A0-E040-BB89AD437544","latestVersionIndicator":"Yes","beginDate":"2012-03-23","endDate":null,"createdBy":"STAUFFEM","dateCreated":"2012-03-23","modifiedBy":"STAUFFEM","dateModified":"2012-03-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}